European Medicines Committee Backs Johnson & Johnson's COVID-19 Booster Dose

  • EMA's human medicines committee (CHMP) has concluded that a booster dose of Johnson & Johnson's PFE COVID-19 vaccine may be considered at least two months after the first dose in people aged 18 years and above.
  • The recommendation follows data showing that a booster dose of COVID-19 vaccine given at least two months after the first dose in adults led to a rise in antibodies against SARS-CoV-2.
  • The risk of thrombosis combined with thrombocytopenia (TTS) or other very rare side effects after a booster is not known and is being carefully monitored. 
  • CHMP also concluded that a booster dose with COVID-19 vaccine might be given after two doses of one of the mRNA vaccines authorized in the EU, Comirnaty, from Pfizer Inc PFEBioNTech SE BNTX or Spikevax, from Moderna Inc MRNA.
  • Related Link: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab.
  • Price Action: JNJ shares are up 0.19% at $170.62 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!